FindTrial
Sign In

Research on the correlation to serum antibody of Helicobacter Pylori and patient of primary hepatic carcinoma who acceptted interventional therapy

Research on the correlation to serum antibody of Helicobacter Pylori and patient of primary hepatic carcinoma who acceptted interventional therapy

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-OOC-15005776
Enrollment
Unknown
Registered
2015-01-05
Start date
2014-12-14
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

primary hepatic carcinoma

Interventions

HP positive group:none
HP negative group:none

Sponsors

The Afiliated Tumor Hospital of Xinjiang Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. all of the patients were primary liver cancer, have definite pathological diagnosis or clinical manifestations of liver cancer and the typical imaging findings of primary liver cancer. (liver cancer diagnosis and staging of reference in 2001, the China association of professional committee of liver cancer revised standard of clinical diagnosis and staging of primary liver cancer); 2. patients are already or will soon interventional therapy with conventional TACE; 3. main organs function is normal, tolerated minimally invasive treatment; 4. physical status score (KPS) more than 70 points.

Exclusion criteria

Exclusion criteria: 1. none primary liver cancer; 2. physical status score (KPS) < 70 points; 3. main viscera serious function failure.

Design outcomes

Primary

MeasureTime frame
infection rate;hepatitis B;liver cirrhosis;AFP(alpha fetoprotein);—

Countries

China

Contacts

Public ContactWu-kui HUANG
huangwukui1982@sina.com+86 15909911798

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026